2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 15:38, 21 November 2023
, 21 November 2023no edit summary
No edit summary |
No edit summary |
||
| Line 126: | Line 126: | ||
| style="vertical-align:top; border:none;" | | | style="vertical-align:top; border:none;" | | ||
* '''Safety''': basically safe under the existing intervention dose and time | * '''Safety''': basically safe under the existing intervention dose and time | ||
* '''Sleep quality''': no significant improvement | * '''Sleep quality''': no significant improvement{{pmid_text|35215405}} | ||
* '''Physical activity''': prevented aging-related muscle dysfunctions and improving physical performance^ | * '''Physical activity''': prevented aging-related muscle dysfunctions and improving physical performance^{{pmid_text|35215405}},{{pmid|35927255}},{{pmid_text|34238308}},35821806 | ||
* '''Ear''': improved the right auditory ability of old men{{pmid|35927255}} | * '''Ear''': improved the right auditory ability of old men{{pmid|35927255}} | ||
* '''Cognition''': no significant improvement{{pmid|35927255}} | * '''Cognition''': no significant improvement{{pmid|35927255}} | ||
* '''Diabetes''': increased muscle insulin sensitivity, insulin signaling, and remodeling in prediabetic women | * '''Diabetes''': increased muscle insulin sensitivity, insulin signaling, and remodeling in prediabetic women{{pmid_text|33888596}} | ||
* '''Telomere''': increased telomere length^ | * '''Telomere''': increased telomere length^34912838 | ||
|} | |} | ||
| Line 312: | Line 311: | ||
|- | |- | ||
|{{pmid text|35927255}} | |{{pmid text|35927255}} | ||
| | |||
| | |||
| | |||
|- | |||
| | |||
* 35821806 | |||
| | |||
| | |||
| | |||
|- | |||
| | |||
* 34912838 | |||
| | | | ||
| | | | ||